Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BCAB | US
0.01
0.51%
Healthcare
Biotechnology
30/06/2024
16/10/2024
1.96
1.99
2.00
1.84
BioAtla Inc. a clinical stage biopharmaceutical company develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011 a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors non-small cell lung cancer (NSCLC) and ovarian cancer. It also develops BA3021 a CAB ADC for multiple solid tumor types including NSCLC melanoma and head and neck cancer; and BA3071 which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma NSCLC small cell lung cancer hepatocellular carcinoma melanoma bladder cancer gastric cancer and cervical cancer. BioAtla Inc. was founded in 2007 and is based in San Diego California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
114.0%1 month
89.0%3 months
88.5%6 months
127.4%-
-
2.97
0.05
0.02
0.31
134.37
-
-108.88M
94.74M
94.74M
-
-
-
31.60
-134.14
7.70
10.33
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.66
Range1M
0.85
Range3M
1.08
Rel. volume
0.77
Price X volume
2.28M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Regulus Therapeutics Inc | RGLS | Biotechnology | 1.59 | 104.09M | 6.00% | n/a | 1.45% |
INmune Bio Inc | INMB | Biotechnology | 5.21 | 103.32M | 7.87% | n/a | 14.65% |
Coherus BioSciences Inc | CHRS | Biotechnology | 0.8866 | 102.14M | -2.58% | n/a | -354.71% |
Agenus Inc | AGEN | Biotechnology | 4.68 | 100.96M | 0.43% | n/a | -170.56% |
AVTX | AVTX | Biotechnology | 10.29 | 99.81M | 6.19% | n/a | -80.47% |
Marinus Pharmaceuticals Inc | MRNS | Biotechnology | 1.8 | 99.15M | 3.45% | n/a | -202.54% |
Oramed Pharmaceuticals Inc | ORMP | Biotechnology | 2.43 | 99.07M | 3.40% | 4.67 | 0.00% |
BeyondSpring Inc | BYSI | Biotechnology | 2.39 | 96.32M | -4.02% | n/a | -14.90% |
Oncolytics Biotech Inc. (USA) | ONCY | Biotechnology | 1.25 | 96.07M | 0.81% | n/a | 0.00% |
bluebird bio Inc | BLUE | Biotechnology | 0.4818 | 93.43M | 0.12% | n/a | 736.91% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.49 | 93.31M | 1.12% | 5.27 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.34 | 89.79M | -0.14% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.5 | 19.04M | 4.17% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.02 | 18.42M | 2.01% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.6542 | 9.49M | -5.19% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2051 | 3.68M | -6.82% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.09 | 2.84M | -0.91% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -0.99% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.42 | 0 | 2.63% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.21 | 0 | 3.19% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.31 | 0.53 | Cheaper |
Ent. to Revenue | 134.37 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 2.97 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 88.51 | 72.92 | Riskier |
Debt to Equity | 0.05 | -1.24 | Expensive |
Debt to Assets | 0.02 | 0.25 | Cheaper |
Market Cap | 94.74M | 3.78B | Emerging |